Last reviewed · How we verify
MIBOLERONE
Mibolerone works by binding to the androgen receptor, mimicking the effects of male hormones.
Mibolerone is a small molecule that targets the androgen receptor, a protein involved in the development and maintenance of male characteristics. It is not FDA-approved for any indications, and its commercial status is unknown. Mibolerone works by binding to the androgen receptor, which can lead to changes in gene expression and cellular function. As a result, it may be used to treat conditions related to androgen excess or deficiency. However, due to its unknown commercial status and lack of FDA approval, its use is not well-established.
At a glance
| Generic name | MIBOLERONE |
|---|---|
| Target | Androgen receptor, Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Mechanism of action
Think of the androgen receptor like a key that unlocks certain genes in your body. When mibolerone binds to this receptor, it's like giving the key to the wrong person - it can cause changes in how your body functions, particularly in terms of male characteristics. This can be useful for treating conditions related to androgen excess or deficiency.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MIBOLERONE CI brief — competitive landscape report
- MIBOLERONE updates RSS · CI watch RSS